Cargando…
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
PURPOSE: Deficiency in homologous recombination (HR) repair of DNA damage is characteristic of many high-grade serous ovarian cancers (HGSC). It is imperative to identify patients with homologous recombination–deficient (HRD) tumors as they are most likely to benefit from platinum-based chemotherapy...
Autores principales: | Pikkusaari, Sanna, Tumiati, Manuela, Virtanen, Anni, Oikkonen, Jaana, Li, Yilin, Perez-Villatoro, Fernando, Muranen, Taru, Salko, Matilda, Huhtinen, Kaisa, Kanerva, Anna, Koskela, Heidi, Tapper, Johanna, Koivisto-Korander, Riitta, Joutsiniemi, Titta, Haltia, Ulla-Maija, Lassus, Heini, Hautaniemi, Sampsa, Färkkilä, Anniina, Hynninen, Johanna, Hietanen, Sakari, Carpén, Olli, Kauppi, Liisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425726/ https://www.ncbi.nlm.nih.gov/pubmed/36805632 http://dx.doi.org/10.1158/1078-0432.CCR-22-3156 |
Ejemplares similares
-
Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer
por: Perez-Villatoro, Fernando, et al.
Publicado: (2022) -
Author Correction: Virtual clinical trials identify effective combination therapies in ovarian cancer
por: Kozłowska, Emilia, et al.
Publicado: (2020) -
Virtual clinical trials identify effective combination therapies in ovarian cancer
por: Kozłowska, Emilia, et al.
Publicado: (2019) -
Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer
por: Oikkonen, Jaana, et al.
Publicado: (2019) -
Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer
por: He, Liye, et al.
Publicado: (2021)